

Docket No.: VPI/02-129 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Mark Ledeboer, et al.

SERIAL NUMBER:

10/657,811

EXAMINER:

Not Yet Assigned

FILING DATE:

September 8, 2003

ART UNIT:

1614

FOR:

ISOXAZOLES AND USES THEREOF

March 16, 2004

Cambridge, Massachusetts

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references.

	This Information Disclosure Statement is being been filed:
	within three months of the filing date of the National Application;
	within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
\boxtimes	before the mailing date of a first Office Action on the merits in the above-identified case.
	Accordingly, no fee or certification is required. (37 C.F.R. §1.97).

A copy of the references are enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

APPLICANTS:

Ledeboer, et al.

U.S.S.N.:

10/657,811

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0725, Reference No. VPI/02-121 US.

Respectfully submitted,

Karoline K. M. Shair, Reg. No. 44,332

Attorney for Applicants

c/o Vertex Pharmaceuticals Incorporated

130 Waverly Street

Cambridge, Massachusetts 02139

Tel: (617) 444-6536 Fax: (617) 444-6483

(P	O 1 P E C 32 MAR 1 9 2004 32	
то	TA TRADEMARKO	

Modified Form 1449/PTO RADEMINE	Application Number	10/657,811	
NOC.	Filing Date	September 8, 2003	
INFORMATION DISCLOSURE	First Named Inventor	Mark Ledeboer	
STATEMENT BY APPLICANT	Group Art Unit	1614	
	Examiner Name	Not Yet Assigned	
(use as many sheets as necessary)	Attorney Docket Number	VPI/02-121 US	

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
					i		

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreig Office	n Patent Document Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Trans Yes	slation No
	BI	wo	01/12621	Vertex Pharamceuticals Incorporated	22 February 2001		
					2		


OTHER NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	Cl	Bozyczko-Coyne, D., et al., "Targeting the JNK Pathway for Therapeutic Benefit in CNS Disease," Curr Drug Targets - CNS and Neurological Disorders, 1(1):31-49 (2002).					
		į					
		1					

* a copy of this reference is not provided as it was pr	reviously cited by or submitted to the office in a prior application,
U.S.S.N, filed	, and relied upon for an earlier filing date under 35 U.S.C. §120
(continuation, continuation-in-part, and divisional ag	pplications).

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.



Certificate Of Mailing Under 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service wih sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

On <u>March 16, 2004</u>
Date

- 1. Information Disclosure Statement (in duplicate);
- 2. PTO-1449 Form (in duplicate); and
- 3. Cited References (B1 and C1);
- 4. This Return Postcard Receipt.

Karen DiRocco

Typed or printed name of person signing Certificate